CAV1 and neoplasm: The results of univariate analyses (Table 2) demonstrated that high-risk patients according to the Clinical Risk Score5 (HR 1.96; 95% CI, 1.22–3.15; P = 0.005), disease progression during neoadjuvant chemotherapy according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria16 (HR 4.60; 95% CI, 2.20–9.60; P < 0.001), no administration of adjuvant post-hepatectomy chemotherapy (HR 2.30; 95% CI, 1.37–3.88; P = 0.002), and weak stromal CAV1 expression (HR 1.78; 95% CI, 1.13–2.83; P = 0.013) were associated with a decreased DFS (Fig. 2).